The shoulder in patients with muscular dystrophy

Citation
Sa. Copeland et al., The shoulder in patients with muscular dystrophy, CLIN ORTHOP, (368), 1999, pp. 80-91
Citations number
29
Categorie Soggetti
Ortopedics, Rehabilitation & Sport Medicine","da verificare
Journal title
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
ISSN journal
0009921X → ACNP
Issue
368
Year of publication
1999
Pages
80 - 91
Database
ISI
SICI code
0009-921X(199911):368<80:TSIPWM>2.0.ZU;2-1
Abstract
Shoulder weakness and instability are not usually a major part of the clini cal picture of muscular dystrophies, Problems usually do not arise until th e patient is wheelchair bound, at which time assistive appliances may be re quired, The majority of orthopaedic intervention is confined to the rare fa cioscapulohumeral dystrophy. Facioscapulohumeral dystrophy causes muscular weakness of the fare, shoulder girdle, and upper arm with selective sparing of the deltoid muscle. This leads to scapular winging and a marked decreas e in flexion and abduction of the shoulder. As the muscles stabilizing the scapula become involved, the scapula starts to wing. The deltoid is spared, but its action is wasted because of the unstable scapula, The deltoid cont racts and the arm attempts to move in a normal fashion, but because the sca pula is no longer stable, it wings and rotates under the forces of the long lever arm of the upper limb and scapula complex, Mechanical fixation of th e scapula to the thoracic wall provides a stable fulcrum on which the delto id can exert its powerful action on the humerus and abduct the arm without rotation of the scapula, Twenty thoracoscapular fusions were performed on 1 3 patients. Ten patients (14 shoulders) were available for long term follow up, The long term results showed that this operation is successful in achie ving stability of the scapula. while greatly improving function and cosmesi s, Although the course of this type of muscular dystrophy is variable, the benefits: of surgery have not deteriorated with progression of the disease during a maximum followup of 34 years.